

NOTICE
NATION INSTRUMENT 51-102
CHANGE OF CORPORATE STRUCTURE

Item 1 Names of the Parties to the Transaction

bioMmune Technologies Inc. (formerly MC Partners Inc.) (the “**Company**”) and bioMmune Advanced Technologies Inc. (formerly bioMmune Technologies Inc.) (“**BAT**”).

Item 2 Description of the Transaction

The Company has acquired (the “**Acquisition**”) all of the issued and outstanding shares of BAT bioMmune Technologies Inc. (formerly MC Partners Inc.) by way of the share exchange, pursuant to which BAT shareholders received one common share of the Company for each BAT common share held. As a result of the Acquisition, BAT is now a wholly-owned subsidiary of the Company.

In connection with the Acquisition, the Company has changed its name to “bioMmune Technologies Inc.”.

The Acquisition served as the Company’s Qualifying Transaction under the policies of the TSX Venture Exchange (the “TSXV”). At open market on Wednesday, May 28, 2013, the Company was classified as a Tier 2 “Biotechnology” company pursuant to the policies of the TSXV, and its common shares commenced trading in the name of “bioMmune Technologies Inc.” under the symbol “IMU”.

There is no change in year end of the Company in connection with the Acquisition, and the Company’s year-end remains November 30. The first interim financial statements that will be reported on a post-Acquisition consolidated basis will be the financial statements for the six-month interim period ended May 31, 2013.

In connection with the Acquisition, the Company also completed a non-brokered private placement of 10,000,000 units (each the “**Unit**”) of the Company at a price of \$0.15 per unit for the gross proceeds of \$1,500,000 (the “**Financing**”). Each unit consists of one common share of the Company and one common share purchase warrant of the Company (the “**Warrant**”). Each whole Warrant entitles the holder to purchase one additional common share of the Company at a price of \$0.25 for a period of 12 months from the completion of the Financing, subject to an exercise acceleration clause. Under the exercise acceleration clause, which the Company may exercise once the Units are free of resale restrictions and if the Company’s shares are trading at or above a volume weighted average price of \$0.40 for more than 20 trading consecutive days, the Warrants will expire upon 30 days from the date the Company provides notice in writing to the Warrant holders via a news release. Pursuant to the terms of the Financing, the Company paid to Haywood Securities Inc. a finder’s fee of \$100,020 and issued a total of 1,000,200 finder’s warrants (each a “**Finder Warrant**”). Each Finder Warrant is exercisable into one common share of the Company for a period of 12 months at a price of \$0.25. The proceeds from the

Financing will be added to working capital in furtherance of the Company's business.

After completion of the Acquisition and the Financing, the Company has 22,600,000 common shares issued and outstanding.

Further details of the Acquisition are set out in the Company's filing statement dated April 26, 2013, which is available for viewing on the SEDAR website (www.sedar.com) under the Company's issuer profile.

Item 3 Effective Date of the Transaction

May 24, 2013

DATED June 5, 2013